文献速递免疫规划慢病防控与筛查卫生政策与健康促进

中国二价人乳头瘤病毒疫苗的卫生经济学评价:基于动态模型

[Health economic evaluation of bivalent human papilloma virus vaccine in China: based on the dynamic model].
PubMed 文献 · Zhonghua Yu Fang Yi Xue Za Zhi · 2017-01-01

研究构建多健康状态动态模型,模拟19项二价HPV疫苗接种与VIA/VILI筛查方案。以不干预为基准,常规接种使宫颈癌发病率降低69.5%,常规接种并3年筛查1次降低89.4%;常规接种并终生筛查2次的ICER为121 292元人民币/年,具有成本效益。

要点

  • 常规接种二价HPV疫苗使宫颈癌发病率降低69.5%,优于仅VIA/VILI筛查方案。
  • 常规接种并3年筛查1次使宫颈癌发病率降低89.4%。
  • 常规接种并终生筛查2次ICER为121 292元人民币/年,具有成本效益。

核心结论

  • 对适龄人群接种二价HPV疫苗并进行VIA/VILI筛查能有效降低宫颈癌发病率,且具有成本效益。

研究设计与样本

  • 构建具有人口异质性的多健康状态动态模型,包含疾病自然史模块和干预模块。
  • 假定疫苗保护力为100%,接种和VIA/VILI筛查覆盖率均为70%。
  • 针对二价HPV疫苗接种和VIA/VILI筛查制定19项干预方案,常规接种为女性15岁时接种3剂次。
  • 从ICER(阈值152 087元人民币)和成本效益边界角度分析,并以不干预为基准进行比较。

主要发现

  • 与不干预相比,常规接种二价HPV疫苗使宫颈癌发病率降低69.5%,优于仅VIA/VILI筛查的5项方案(范围9.0%至69.2%)。
  • 常规接种并终生筛查1次使宫颈癌发病率降低72.0%。
  • 常规接种并3年筛查1次使宫颈癌发病率降低89.4%。
  • 与不干预相比,常规接种并终生筛查2次的ICER为121 292元人民币/年,具有成本效益。
  • 疫苗价格小于600元人民币时,仅常规接种或常规接种后16~39岁补种具有成本效益;小于1 200元人民币时,16~29岁补种并适时VIA/VILI筛查具有成本效益。

关键数值与推荐

  • ICER阈值为152 087元人民币。
  • 常规接种并终生筛查2次的ICER为121 292元人民币/年。
  • 疫苗价格小于600元人民币时,仅常规接种或常规接种后16~39岁补种具有成本效益。
  • 疫苗价格小于1 200元人民币时,16~29岁补种并适时VIA/VILI筛查具有成本效益。

临床怎么用

  • 对适龄人群接种二价HPV疫苗并进行VIA/VILI筛查能有效降低宫颈癌发病率,且具有成本效益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study aims to evaluate the prevention effect and cost-effectiveness of a prophylactic bivalent human papilloma virus (HPV) vaccine. Methods: A multiple health status dynamic model was developed, including natural history of diseases and prevention strategies. We built 19 prevention strategies including visual inspection with acetic acid/lugol's iodine (VIA/VILI) and/or 3 does prophylactic bivalent HPV vaccine administered to adolescent girls at the age of 15 years old every year under the assumption that vaccine coverage and screening coverage were 70%. The incremental cost-effectiveness ratio (ICER), optimal price of 3 does vaccine and cost-effectiveness frontier of these strategies were analyzed compared with no-intervention. The ICER threshold is 152 087 CNY. Results: Compared with no-intervention, Routine vaccination reduced the incidence of cervical cancer by 69.5%, superior to 5 strategies including VIA/VILI screening only. The range of effect was between 9.0% and 69.2%, and the effect of strategy increased significantly with the increase of screening frequency. Combination vaccination with screening at ages of 35 reduced the incidence of cervical cancer by 72.0%, and the effect increased with the increase of screening frequency. Combination vaccination with screening every 3 years between (35-64) years old reduced the incidence by 89.4%. Compared with no-intervention, the ICER of combination vaccination with screening twice between 35 years and 64 years was 121 292 CNY/life-year, which was cost-effective. The price of vaccine had a significant impact on the ICER of the strategy; when the vaccine price was less than 600 CNY, only routine vaccination or supplementary vaccination between 16-39 years old after routine vaccination was cost-effective; when the vaccine price was less than 1 200 CNY, supplementary vaccination between 16-19 years old plus VIA/VILI was cost-effective. Conclusion: Ther prevention strategy was cost-effective, which could effectively reduce the incidence of cervical cancer by implementation of HPV vaccination combined with VIA/VILI in suitable aging females. 目的: 对接种二价HPV疫苗的预防效果及成本效益进行卫生经济学评价。 方法: 构建适用于我国的具有人口异质性的多健康状态的动态模型,模型包含疾病自然史模块和干预模块;假定疫苗保护力为100%,接种和醋酸染色检查/复方碘染色方法(VIA/VILI)筛查的覆盖率均为70%的前提下,针对接种二价HPV疫苗和VIA/VILI筛查制定19项干预方案,方案中设定常规接种为女性15岁时接种3剂次二价HPV疫苗。通过多健康状态的动态模型模拟19项干预方案的长期效果与成本,本研究从增量成本效益比(ICER,以152 087元人民币为具有成本效益的阈值)和成本效益边界角度对方案进行分析,同时采用阈值分析法分析各方案中疫苗的最优价格,并以不干预为基准进行比较。 结果: 与不进行干预相比,常规接种二价HPV疫苗可使宫颈癌发病率降低69.5%,优于仅进行VIA/VILI筛查的5项方案(最低为9.0%,最高为69.2%,预防效果随筛查频率提高而显著提高);常规接种并终生筛查1次使宫颈癌发病率降低72.0%,常规接种并3年筛查1次使发病率降低达89.4%。与不进行干预相比,常规接种并终生筛查2次的ICER为121 292元人民币/年,具有成本效益。疫苗价格对方案的成本效益具有较大影响,当疫苗价格小于600元人民币,仅常规接种或常规接种后在16~39岁时补种的方案具有成本效益;当疫苗价格小于1 200元人民币时,在16~29岁时补种并适时进行VIA/VILI筛查的方案具有成本效益。 结论: 对适龄人群接种二价HPV疫苗并进行VIA/VILI筛查能有效降低宫颈癌发病率,且具有成本效益的预防策略。.

来源:Zhonghua Yu Fang Yi Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Song XB, Zhao QJ, Zhou Z, et al. [Health economic evaluation of bivalent human papilloma virus vaccine in China: based on the dynamic model]. Zhonghua Yu Fang Yi Xue Za Zhi. 2017. PMID: 28881547. doi:10.3760/cma.j.issn.0253-9624.2017.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。